Cargando…

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements

BACKGROUND: It is known that lung function decline in Alpha-1 Antitrypsin Deficiency (AATD) varies. Those with a rapid decline are at highest risk of poorer outcomes but may benefit most from targeted treatments including augmentation therapy. Current evidence suggests rapid decliners can be identif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stockley, James A, Stockley, Robert A, Sapey, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018552/ https://www.ncbi.nlm.nih.gov/pubmed/33824583 http://dx.doi.org/10.2147/COPD.S298585

Ejemplares similares

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

The rs361525 polymorphism does not increase production of tumor necrosis factor alpha by monocytes from alpha-1 antitrypsin deficient subjects with chronic obstructive pulmonary disease - a pilot study
por: Gane, Jennie M., et al.
Publicado: (2015)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

A specific proteinase 3 activity footprint in α(1)-antitrypsin deficiency
por: Newby, Paul R., et al.
Publicado: (2019)

Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD
por: Hampson, Judith A., et al.
Publicado: (2016)

Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
por: Stockley, Robert A., et al.
Publicado: (2018)

The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency
por: Wood, Alice M, et al.
Publicado: (2008)

Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD
por: Vijayasaratha, Kesavaperumal, et al.
Publicado: (2012)

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency
por: Duckers, James M, et al.
Publicado: (2010)

Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; Methodological advances
por: Parr, David G, et al.
Publicado: (2008)

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
por: Stockley, Robert A, et al.
Publicado: (2016)

Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review
por: Edgar, Ross G, et al.
Publicado: (2017)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote
por: Sinden, Nicola Jane, et al.
Publicado: (2014)

Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative
por: Crossley, Diana, et al.
Publicado: (2020)

Getting stuck or choosing to stay? Neutrophil transit times in the lung in acute inflammation and COPD
por: Sapey, Elizabeth, et al.
Publicado: (2019)

Small airways disease: time for a revisit?
por: Stockley, James A, et al.
Publicado: (2017)

An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways' function guide diagnosis and management?
por: Alobaidi, Nowaf Y., et al.
Publicado: (2020)

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021)

Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study
por: Alobaidi, Nowaf Y, et al.
Publicado: (2022)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases
por: Crisford, Helena, et al.
Publicado: (2018)

The diagnosis of asthma. Can physiological tests of small airways function help?
por: Almeshari, Mohammed A, et al.
Publicado: (2021)

The prevalence of bronchodilator responsiveness of the small airway (using mid-maximal expiratory flow) in COPD - a retrospective study
por: Alobaidi, Nowaf Y., et al.
Publicado: (2022)

Small airways dysfunction: The importance of utilising Z-scores to define MMEF abnormalities in clinical practice
por: Almeshari, Mohammed A., et al.
Publicado: (2023)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Identifying Alpha-1 Antitrypsin Deficiency Based on Computed Tomography Evidence of Emphysema
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

TNF-α Autocrine Feedback Loops in Human Monocytes: The Pro- and Anti-Inflammatory Roles of the TNF-α Receptors Support the Concept of Selective TNFR1 Blockade In Vivo
por: Gane, Jennie M., et al.
Publicado: (2016)

Catching “Early” COPD – The Diagnostic Conundrum
por: Yip, Kay Por, et al.
Publicado: (2021)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review
por: Almeshari, Mohammed A, et al.
Publicado: (2021)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8iuv5fjag9f2dhicn8m1maka8t